Testing shorter breast radiation after low-risk hormone breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to the study and (if in the U.S.) allow the team to get your medical records.
- Your performance status must be 0 or 1, meaning you’re able to carry out daily activities with little or no limitation.
- You had a lumpectomy (not mastectomy) and your surgical margins must be free of invasive cancer and DCIS on the final pathology report.
- Your cancer must be on one side only, with staging showing pT1 (2 cm or smaller) and pN0 nodes (no node cancer).
- Your tumor must be estrogen-positive and/or progesterone-positive, and HER2-negative.
- Your Oncotype DX Recurrence Score must be 18 or less (and you should not start endocrine therapy before the tissue sample).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a lower dose of treatment for women with small, early-stage breast cancer that is hormone-positive and has not spread to lymph nodes. The goal is to find out if it can be as effective as the standard treatment with fewer side effects.
This trial tests whether taking hormone therapy for 3 months before breast-conserving surgery can help doctors decide if radiation is right for you. It is for women aged 65 and older with a common type of breast cancer that is hormone receptor-positive and HER2-negative.
This Phase 2 trial tests a shorter, focused radiation treatment after breast surgery, either alone or with an extra targeted boost. It’s for people with low-risk breast cancer and no spread to distant organs, aiming to keep results while reducing treatment time and side effects.
This Phase 3 trial tests whether a shorter, more focused radiation treatment to the regional lymph nodes works as well as the current standard approach for certain breast cancers. It may help patients by potentially improving treatment efficiency while keeping cancer control effective.
This trial tests whether older women with very low-risk, hormone-positive breast cancer can safely skip endocrine therapy (hormone-blocking pills) and radiation after lumpectomy. It aims to maintain quality of life while keeping cancer from coming back.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
Hear when a new Stage I Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.